Filters

Clear all

Expert Opinion

Plain Language Summary

Expert Review

Text Availability

Abstract

Full text

Free full text

Publication Types

Journal Article

Research Support, Non-U.S. Gov't

Clinical Trial

Randomized Controlled Trial

Review

Research Support, U.S. Gov't, P.H.S.

Comparative Study

Research Support, U.S. Gov't, Non-P.H.S.

Controlled Clinical Trial

Research Support, N.I.H., Extramural

Multicenter Study

Publication Year

From

Quick links

Individual year

2022

2019

2016

2011

2006

2005

2004

2003

2002

2001

2000

Sort by:

selected

Print page

Email selected articles

Favourite selected articles

Create a NED Search Alert for this search

Save this search

Advanced Search

Run an advanced search

Results for
""Apolipoproteins C""[mesh_terms]

27 Results

Searching titles within these results

Is Apo-CIII the new cardiovascular target? An analysis of its current clinical and dietetic therapies.

Lorenzo G de la Parra Soto, Janet A Gutiérrez-Uribe, Ashutosh Sharma, Aurea K Ramírez-Jiménez

Nutrition, metabolism, and cardiovascular diseases : NMCD 2022;32(2):295-308

Full Text

Abstract

Greater enrichment of triacylglycerol-rich lipoproteins with apolipoproteins E and C-III after meals rich in saturated fatty acids than after meals rich in unsaturated fatty acids.

Parveen Yaqoob, Paul A Bateman, Emma J Wolstencroft, Kim G Jackson, Christine M Williams

The American journal of clinical nutrition 2005;81(1):25-34

Free Full Text

Abstract

Effect of genetic variation on the postprandial response. Results from the European Atherosclerosis Research Study II.

S E Humphries, D M Waterworth, P J Talmud

World review of nutrition and dietetics 2001;89():53-60

Full Text

Variations in plasma apolipoprotein C-III levels are strong correlates of the triglyceride response to a high-monounsaturated fatty acid diet and a high-carbohydrate diet.

Bénédicte Fontaine-Bisson, Nancy Landry, Olivier Dériaz, Nathalie Bergeron, Jean Bergeron, Sophie Desroches, Patrick Couture, Benoit Lamarche, W Roodly Archer

Metabolism: clinical and experimental 2005;54(10):1390-7

Full Text

Abstract

Contributions of domain structure and lipid interaction to the functionality of exchangeable human apolipoproteins.

Sissel Lund-Katz, Michael C Phillips, Hiroyuki Saito

Progress in lipid research 2004;43(4):350-80

Full Text

Abstract

Effect of pravastatin on apolipoproteins B and C-III in very-low-density lipoproteins and low-density lipoproteins.

Frank M Sacks, Petar Alaupovic, Lemuel A Moye

The American journal of cardiology 2002;90(2):165-7

Full Text

Hypertriglyceridemia, the coronary heart disease risk marker "solved".

A Császár

Acta physiologica Hungarica 2005;92(2):109-20

Full Text

Abstract

Apolipoprotein E and apolipoprotein CI polymorphisms in the Czech population: almost complete linkage disequilibrium of the less frequent alleles of both polymorphisms.

J A Hubácek, J Pitha, V Adámková, Z Skodová, V Lánská, R Poledne

Physiological research 2004;52(2):195-200

Free Full Text

Abstract

Association between MspI polymorphism of the APO AI gene and Type 2 diabetes mellitus.

S Morcillo, F Cardona, G Rojo-Martínez, I Esteva, M S Ruíz-de-Adana, F Tinahones, J M Gómez-Zumaquero, F Soriguer

Diabetic medicine : a journal of the British Diabetic Association 2005;22(6):782-8

Full Text

Abstract

The effects of varying doses of T on insulin sensitivity, plasma lipids, apolipoproteins, and C-reactive protein in healthy young men.

Atam B Singh, Stanley Hsia, Petar Alaupovic, Indrani Sinha-Hikim, Linda Woodhouse, Thomas A Buchanan, Ruoquing Shen, Rachelle Bross, Nancy Berman, Shalender Bhasin

The Journal of clinical endocrinology and metabolism 2002;87(1):136-43

Full Text

Abstract

Atorvastatin decreases apolipoprotein C-III in apolipoprotein B-containing lipoprotein and HDL in type 2 diabetes: a potential mechanism to lower plasma triglycerides.

Geesje M Dallinga-Thie, Ingrid I L Berk-Planken, Aart H Bootsma, Hans Jansen

Diabetes care 2005;27(6):1358-64

Full Text

Abstract

Genetic disorders of the pancreas.

Véronique Morinville, Jean Perrault

Gastroenterology clinics of North America 2003;32(3):763-87

Full Text

Abstract

Impact of Novel Low-Density Lipoprotein-Cholesterol Assessment on the Utility of Secondary Non-High-Density Lipoprotein-C and Apolipoprotein B Targets in Selected Worldwide Dyslipidemia Guidelines.

Vasanth Sathiyakumar, Jihwan Park, Renato Quispe, Mohamed B Elshazly, Erin D Michos, Maciej Banach, Peter P Toth, Seamus P Whelton, Roger S Blumenthal, Steven R Jones, Seth S Martin

Circulation 2019;138(3):244-254

Full Text

Abstract

Effect of pravastatin on intermediate-density and low-density lipoproteins containing apolipoprotein CIII in patients with diabetes mellitus.

Frank M Sacks, Sung-Joon Lee

The American journal of cardiology 2003;92(2):121-4

Full Text

Abstract

Genetic determinants of low high-density lipoprotein cholesterol.

Min Zhan, Michael Miller

Current opinion in cardiology 2005;19(4):380-4

Full Text

Abstract

Results: 1 – 15 / 27

Filters

Expert Opinion

Text Availability

Publication Types

Publication Year

Results for ""Apolipoproteins C""[mesh_terms]

Is Apo-CIII the new cardiovascular target? An analysis of its current clinical and dietetic therapies.

Greater enrichment of triacylglycerol-rich lipoproteins with apolipoproteins E and C-III after meals rich in saturated fatty acids than after meals rich in unsaturated fatty acids.

Effect of genetic variation on the postprandial response. Results from the European Atherosclerosis Research Study II.

Variations in plasma apolipoprotein C-III levels are strong correlates of the triglyceride response to a high-monounsaturated fatty acid diet and a high-carbohydrate diet.

Contributions of domain structure and lipid interaction to the functionality of exchangeable human apolipoproteins.

Effect of pravastatin on apolipoproteins B and C-III in very-low-density lipoproteins and low-density lipoproteins.

Hypertriglyceridemia, the coronary heart disease risk marker "solved".

Apolipoprotein E and apolipoprotein CI polymorphisms in the Czech population: almost complete linkage disequilibrium of the less frequent alleles of both polymorphisms.

Association between MspI polymorphism of the APO AI gene and Type 2 diabetes mellitus.

The effects of varying doses of T on insulin sensitivity, plasma lipids, apolipoproteins, and C-reactive protein in healthy young men.

Atorvastatin decreases apolipoprotein C-III in apolipoprotein B-containing lipoprotein and HDL in type 2 diabetes: a potential mechanism to lower plasma triglycerides.

Genetic disorders of the pancreas.

Impact of Novel Low-Density Lipoprotein-Cholesterol Assessment on the Utility of Secondary Non-High-Density Lipoprotein-C and Apolipoprotein B Targets in Selected Worldwide Dyslipidemia Guidelines.

Effect of pravastatin on intermediate-density and low-density lipoproteins containing apolipoprotein CIII in patients with diabetes mellitus.

Genetic determinants of low high-density lipoprotein cholesterol.

Results for
""Apolipoproteins C""[mesh_terms]